BioSpace News Archive

CM Life Sciences II Inc. (the “Company”) announced today that it closed its initial public offering of 27,600,000 units at $10.00 per unit, including 3,600,000 units issued pursuant to the exercise in full by the underwriter of its over-allotment option.

ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced that Dr. David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will be presenting and hosting one-on-one meetings with investors at three upcoming virtual investor conferences.